Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Autism - Pipeline Review, H2 2012
Publication Date Aug 2012
Publisher Global Markets Direct
Product Type Report
Pages 86
Single User License $ 2000.00
Site User License $ 4000.00
Corporate User License $ 6000.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Autism - Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Autism - Pipeline Review, H2 2012', provides an overview of the Autism therapeutic pipeline. This report provides information on the therapeutic development for Autism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autism. 'Autism - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Autism.
- A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Autism pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Autism.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Autism therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Autism Therapeutic Products under Development, Key Players in Autism Therapeutics, Autism Pipeline Overview, Autism Pipeline, Autism Pipeline Assessment

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Autism Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Autism 10
Autism Therapeutics under Development by Companies 12
Autism Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Autism Therapeutics - Products under Development by Companies 20
Autism Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Autism Therapeutics Development 23
F. Hoffmann-La Roche Ltd. 23
Sigma-Tau S.p.A. 24
Shenzhen Beike Biotechnology Co., Ltd. 25
Seaside Therapeutics 26
Snowdon Inc. 27
Curemark, LLC 28
Cellceutix Pharmaceuticals, Inc. 29
Heptares Therapeutics Ltd. 30
Autism - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
CM-AT - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
arbaclofen - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Celexa - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Mecamylamine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
N-Acetylcysteine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
KM-391 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
N-Acetylcysteine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Zyprexa - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Bumentanide - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Oxytocin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Bumetanide - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Oxytocin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Risperidone + Celecoxib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 54
Buspirone - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Aripiprazole - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Aripiprazole + D-Cycloserine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 58
D-Cycloserine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Aripiprazole - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Oxytocin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Risperidone - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Program For Neurological Disorders - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
mGluR5 Modulator - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Human Cord Blood Mononuclear Cells + Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Memantine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Human Cord Blood Mononuclear Cells - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
STX110 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
RG7314 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Autism Therapeutics - Drug Profile Updates 71
Autism Therapeutics - Discontinued Products 75
Autism Therapeutics - Dormant Products 76
Autism - Product Development Milestones 79
Featured News & Press Releases 79
Aug 15, 2012: Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs 79
Aug 06, 2012: Curemark To Enroll Children 9-12 Years Of Age Into Medical Trial Of CM-AT For Children With Autism 79
May 31, 2012: Study Reports New Treatment For Irritability In Autism 79
Mar 27, 2012: Seaside Therapeutics Obtains Key Patent For Autism Drug Candidate STX209 80
Dec 07, 2011: Curemark Reports Positive Phase III Results Of CM-AT In Children With Autism 81
Jul 08, 2011: Seaside Presents Phase IIa Data On STX209 In Autism Spectrum Disorders At 42nd Autism Society National Conference 82
Jun 21, 2011: Seaside Therapeutics Initiates Phase IIb Study Of STX209 In Autism Spectrum Disorders 82
Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism 83
Oct 27, 2010: Curemark Adds Two Autism Trial Sites In California 83
Sep 09, 2010: Seaside Reports Positive Data From Phase II Study Of STX209 In Autism Spectrum Disorders 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Tables
List of Tables
Number of Products Under Development for Autism, H2 2012 10
Products under Development for Autism - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 22
F. Hoffmann-La Roche Ltd., H2 2012 23
Sigma-Tau S.p.A., H2 2012 24
Shenzhen Beike Biotechnology Co., Ltd., H2 2012 25
Seaside Therapeutics, H2 2012 26
Snowdon Inc., H2 2012 27
Curemark, LLC, H2 2012 28
Cellceutix Pharmaceuticals, Inc., H2 2012 29
Heptares Therapeutics Ltd., H2 2012 30
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 36
Autism Therapeutics - Drug Profile Updates 71
Autism Therapeutics - Discontinued Products 75
Autism Therapeutics - Dormant Products 76
Autism Therapeutics - Dormant Products (Contd..1) 77
Autism Therapeutics - Dormant Products (Contd..2) 78

List of Figures
List of Figures
Number of Products under Development for Autism, H2 2012 10
Products under Development for Autism - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Discovery and Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Route of Administration, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Molecule Type, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 36

Title Date Price
2013 Deep Research Report on China Human Use Rabies Vaccine Industry
By QYResearch
2013 Deep Research Report on China Human Use Rabie Vaccine Industry is a professional and depth research report on China Human Use Rabies Vaccine industry. This report has firstly introduced Human Use ...Read More
Jan 2013 $2000.00
By Netscribes (India) Pvt. Ltd.
May 2012 $0.00
Medical Devices Market in Russia 2009-2013
By Infiniti Research Ltd
Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
Mar 2010 $1500.00
1300 Smiles Limited (ONT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
By GlobalData
Summary1300 Smiles Limited (1300 Smiles) is a dental service company based in Australia. The company provides dentistry services to patients that include dental surgeries, practice management and othe ...Read More
Jan 2013 $250.00
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances Profile
By GlobalData
2010 Perfect Vision GmbH - Medical Equipment - Deals and Alliances ProfileSummary20/10 Perfect Vision AG is engaged in the development, manufacturing and marketing of innovative technologies for raisi ...Read More
Jan 2012 $250.00
2010 U.S. Ambulatory Surgical & Emergency Centers Industry Report
By Barnes Reports
The U.S Ambulatory Surgical & Emergency Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features ...Read More
Jan 2010 $149.00
2010 U.S. Biological Product Manufacturing Industry Report
By Barnes Reports
The U.S. Biological Product Manufacturing Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 ...Read More
Jan 2010 $149.00
2010 U.S. HMO Medical Centers Industry Report
By Barnes Reports
The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
Jan 2010 $149.00
2010 U.S. Home Health Care Services Industry Report
By Barnes Reports
The Home Health Care Services Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and ...Read More
Oct 2009 $149.00
2010 U.S. Kidney Dialysis Centers Industry Report
By Barnes Reports
The U.S Kidney Dialysis Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current an ...Read More
Jan 2010 $149.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z